^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MAP2K1 P124S

    i
    Other names: MAP2K1, MAPKK1, MEK1, PRKMK1, Mitogen-activated protein kinase kinase 1
    Entrez ID:
    5604
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    6ms
    A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1b, N=6, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2027 --> Oct 2023 | Trial primary completion date: Sep 2027 --> Oct 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124
    |
    fulvestrant • mirdametinib (PD-0325901)
    10ms
    A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1b, N=6, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=150 --> 6
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124
    |
    fulvestrant • mirdametinib (PD-0325901)
    11ms
    A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1b, N=150, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124
    |
    fulvestrant • mirdametinib (PD-0325901)
    over2years
    [VIRTUAL] Mutation Detection in Circulating Tumor Cells at the SingleCell Level Using the MassARRAY System (AMP 2021)
    We have established a novel, straightforward protocol to detect mutation directly from CTC without preamplification at the single cell level. We expect that this workflow will facilitate the exploration of genetic content of CTC, thereby increasing its potential use in the clinic
    Circulating tumor cells
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF V600E • NRAS mutation • BRAF V600 • EGFR T790M • PIK3CA H1047R • KRAS G12V • NRAS Q61K • KRAS G12 • NRAS Q61 • NRAS Q61R • MAP2K1 P124S • MAP2K1 C121S • KRAS Q61K • MAP2K1 P124 • CDK4 mutation
    |
    CELLSEARCH® • Parsortix Liquid Biopsy
    over2years
    A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1b, N=150, Recruiting, Memorial Sloan Kettering Cancer Center
    Clinical • New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NF1 (Neurofibromin 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124
    |
    fulvestrant • mirdametinib (PD-0325901)
    over3years
    Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib. (PubMed, Int J Mol Sci)
    Hence, trametinib could dissociate from the active mutants (P124S and E203K) more easily compared with the WT MEK1. In summary, our theoretical results demonstrated that the active mutations may attenuate the inhibitory effects of MEK inhibitor (trametinib) on MEK1, which could be crucial clues for future anti-cancer treatment.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    KRAS mutation • ALK positive • MAP2K1 mutation • EGFR positive • MAP2K1 P124S • MAP2K1 E203K • MAP2K1 P124
    |
    Mekinist (trametinib)
    over3years
    Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. (PubMed, Cancers (Basel))
    Our results support the utility of ctDNA-Seq to guide treatment allocation for patients with resistance and the importance of investigating further non-canonical EGFR-Ab resistance mechanisms, such as microenvironmentally-mediated resistance. The detection of MAP2K1 mutations could inform trials of MEK-inhibitors in these tumours.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    KRAS mutation • HER-2 amplification • HER-2 mutation • MAP2K1 mutation • MAP2K1 P124S • MAP2K1 P124